Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds.

[1]  B. Travi,et al.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection , 2021, Antimicrobial agents and chemotherapy.

[2]  J. Beijnen,et al.  An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. , 2021, International journal of antimicrobial agents.

[3]  C. Sanmartín,et al.  New Phosphoramidates Containing Selenium as Leishmanicidal Agents , 2021, Antimicrobial agents and chemotherapy.

[4]  Kyung-Hwa Baek,et al.  Discovery of Leishmania donovani topoisomerase IB selective inhibitors by targeting protein-protein interactions between the large and small subunits. , 2021, Biochemical and biophysical research communications.

[5]  Y. Pérez-Pertejo,et al.  Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. , 2021, ACS infectious diseases.

[6]  I. Sharifi,et al.  Determinants of Unresponsiveness to Treatment in Cutaneous Leishmaniasis: A Focus on Anthroponotic Form Due to Leishmania tropica , 2021, Frontiers in Microbiology.

[7]  Peter G. Dodd,et al.  Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis , 2021, Journal of medicinal chemistry.

[8]  A. Bartoloni,et al.  Efficacy and safety of Pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. , 2021, Journal of travel medicine.

[9]  S. Sasidharan,et al.  Leishmaniasis: where are we and where are we heading? , 2021, Parasitology Research.

[10]  F. Tacchini-Cottier,et al.  The Impact of Neutrophil Recruitment to the Skin on the Pathology Induced by Leishmania Infection , 2021, Frontiers in Immunology.

[11]  P. Ghosh,et al.  The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death. , 2021, Parasitology international.

[12]  Alane Beatriz Vermelho,et al.  Identification of Chalcone Derivatives as Inhibitors of Leishmania infantum Arginase and Promising Antileishmanial Agents , 2021, Frontiers in Chemistry.

[13]  R. Pandey,et al.  Neutrophils and Visceral Leishmaniasis: Impact on innate immune response and cross‐talks with macrophages and dendritic cells , 2020, Journal of cellular physiology.

[14]  D. Mukherjee,et al.  Targeting the Trypanothione Reductase of Tissue-Residing Leishmania in Hosts' Reticuloendothelial System: A Flexible Water-Soluble Ferrocenylquinoline-Based Preclinical Drug Candidate. , 2020, Journal of medicinal chemistry.

[15]  Angshuman Bagchi,et al.  Bioassay-based Corchorus capsularis L. leaf-derived β-sitosterol exerts antileishmanial effects against Leishmania donovani by targeting trypanothione reductase , 2020, Scientific Reports.

[16]  A. B. Reis,et al.  Recent advances and new strategies on leishmaniasis treatment , 2020, Applied Microbiology and Biotechnology.

[17]  F. Supek,et al.  Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases , 2020, Journal of medicinal chemistry.

[18]  P. Fokou,et al.  Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol , 2020 .

[19]  O. Kamenyeva,et al.  The role of dermis resident macrophages and their interaction with neutrophils in the early establishment of Leishmania major infection transmitted by sand fly bite , 2020, bioRxiv.

[20]  N. Moretti,et al.  Preclinical gold complexes as oral drug candidates to treat leishmaniasis are potent trypanothione reductase inhibitors. , 2020, ACS infectious diseases.

[21]  A. Ilari,et al.  Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases , 2020, Molecules.

[22]  R. Madhubala,et al.  Epigenetic regulation of defense genes by histone deacetylase1 in human cell line-derived macrophages promotes intracellular survival of Leishmania donovani , 2020, PLoS neglected tropical diseases.

[23]  B. Arana,et al.  CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis , 2020, PLoS neglected tropical diseases.

[24]  Samuel Silva da Rocha Pita,et al.  Novel Scaffolds for Leishmania infantum Trypanothione Reductase Inhibitors Derived from Brazilian Natural Products Biodiversity , 2020 .

[25]  M. Siddiqi,et al.  Identification of potential anti-leishmanial agents using computational investigation and biological evaluation against trypanothione reductase , 2020, Journal of biomolecular structure & dynamics.

[26]  V. Sarmento,et al.  Orofacial manifestations of mucocutaneous leishmaniasis: a case series from Brazil , 2020, F1000Research.

[27]  A. Khamesipour,et al.  An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. , 2019, Acta tropica.

[28]  Y. Pérez-Pertejo,et al.  Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB , 2019, International journal for parasitology. Drugs and drug resistance.

[29]  R. Castillo,et al.  Leishmania mexicana Trypanothione Reductase Inhibitors: Computational and Biological Studies , 2019, Molecules.

[30]  M. N. Rennó,et al.  Phenylhydrazides as inhibitors of Leishmania amazonensis arginase and antileishmanial activity. , 2019, Bioorganic & medicinal chemistry.

[31]  A. Rehman,et al.  Natural compounds from plants controlling leishmanial growth via DNA damage and inhibiting trypanothione reductase and trypanothione synthetase: an in vitro and in silico approach , 2019, 3 Biotech.

[32]  Kapish Kapoor.  COUMARIN ANALOGUES AS A POTENTIAL INHIBITOR OF LEISHMANIASIS: A MULTI-TARGETING PROTEIN INHIBITION APPROACH BY MOLECULAR DOCKING , 2019, Universal Journal of Pharmaceutical Research.

[33]  S. Croft,et al.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis , 2019, International journal for parasitology. Drugs and drug resistance.

[34]  S. Sundar,et al.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development , 2019, Expert opinion on drug metabolism & toxicology.

[35]  Y. Pérez-Pertejo,et al.  Current and promising novel drug candidates against visceral leishmaniasis , 2019, Pure and Applied Chemistry.

[36]  R. Sherkat,et al.  Leishmania Vaccines Entered in Clinical Trials: A Review of Literature , 2019, International journal of preventive medicine.

[37]  R. Balaña-Fouce,et al.  Walking a tightrope: drug discovery in visceral leishmaniasis. , 2019, Drug discovery today.

[38]  F. Gago,et al.  Pyrrolopyrimidine vs Imidazole-Phenyl-Thiazole Scaffolds in Nonpeptidic Dimerization Inhibitors of Leishmania infantum Trypanothione Reductase. , 2019, ACS infectious diseases.

[39]  Juan A. Bueren-Calabuig,et al.  Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition , 2019, Proceedings of the National Academy of Sciences.

[40]  B. Arana,et al.  Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases , 2019, Parasite epidemiology and control.

[41]  V. Yardley,et al.  Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis , 2019, International journal for parasitology. Drugs and drug resistance.

[42]  E. Deeks.  Fexinidazole: First Global Approval , 2019, Drugs.

[43]  Muthukumaran Sivashanmugam,et al.  Virtual screening of natural inhibitors targeting ornithine decarboxylase with pharmacophore scaffolding of DFMO and validation by molecular dynamics simulation studies , 2019, Journal of biomolecular structure & dynamics.

[44]  David W. Gray,et al.  Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis , 2018, Journal of medicinal chemistry.

[45]  V. C. de Souza,et al.  Insights about resveratrol analogs against trypanothione reductase of Leishmania braziliensis: Molecular modeling, computational docking and in vitro antileishmanial studies , 2018, Journal of biomolecular structure & dynamics.

[46]  Simone Brogi,et al.  Cinnamic acids derived compounds with antileishmanial activity target Leishmania amazonensis arginase , 2018, Chemical biology & drug design.

[47]  M. Gramiccia,et al.  Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening , 2018, PLoS neglected tropical diseases.

[48]  A. Pegg.  Introduction to the Thematic Minireview Series: Sixty plus years of polyamine research , 2018, The Journal of Biological Chemistry.

[49]  M. Phillips.  Polyamines in protozoan pathogens , 2018, The Journal of Biological Chemistry.

[50]  J. Lindoso,et al.  Visceral leishmaniasis and HIV coinfection: current perspectives , 2018, HIV/AIDS.

[51]  A. Pegg,et al.  Polyamine metabolism and cancer: treatments, challenges and opportunities , 2018, Nature Reviews Cancer.

[52]  S. Croft,et al.  Leishmaniasis , 2018, The Lancet.

[53]  A. Rabello,et al.  Development and initial validation of a cutaneous leishmaniasis impact questionnaire , 2018, PloS one.

[54]  V. Dubey,et al.  Identification of two natural compound inhibitors of Leishmania donovani Spermidine Synthase (SpdS) through molecular docking and dynamic studies , 2018, Journal of biomolecular structure & dynamics.

[55]  Michael D. Urbaniak,et al.  Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis , 2018, Nature.

[56]  A. Ilari,et al.  Toward a Drug Against All Kinetoplastids: From LeishBox to Specific and Potent Trypanothione Reductase Inhibitors. , 2018, Molecular pharmaceutics.

[57]  F. Belluti,et al.  Identification of chalcone-based antileishmanial agents targeting trypanothione reductase. , 2018, European journal of medicinal chemistry.

[58]  F. Gago,et al.  Trypanothione reductase inhibition and anti-leishmanial activity of all-hydrocarbon stapled α-helical peptides with improved proteolytic stability. , 2018, European journal of medicinal chemistry.

[59]  S. Akhtar,et al.  Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis. , 2018, Nanomedicine.

[60]  H. Coles,et al.  Paromomycin , 2020, Reactions Weekly.

[61]  M. Siddiqi,et al.  Ammonium trichloro [1,2-ethanediolato-O,O′]-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway , 2018, Cellular and Molecular Life Sciences.

[62]  S. Sundar,et al.  Chemotherapeutics of visceral leishmaniasis: present and future developments , 2017, Parasitology.

[63]  B. Arana,et al.  Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme. , 2017, PLoS neglected tropical diseases.

[64]  L. Floeter-Winter,et al.  L-arginine availability and arginase activity: Characterization of amino acid permease 3 in Leishmania amazonensis , 2017, PLoS neglected tropical diseases.

[65]  S. Sundar,et al.  Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi‐subunit topoisomerase IB , 2017, Biochemical pharmacology.

[66]  T. E. Richardson,et al.  Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity. , 2017, Bioorganic & medicinal chemistry.

[67]  R. Arenas,et al.  Leishmaniasis: a review , 2017, F1000Research.

[68]  A. Desideri,et al.  Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B , 2017, Antimicrobial Agents and Chemotherapy.

[69]  S. Esposito,et al.  Visceral leishmaniosis in immunocompromised host: an update and literature review , 2017, Journal of chemotherapy.

[70]  C. Daniliuc,et al.  Anti-leishmanial and cytotoxic activities of amino acid-triazole hybrids: Synthesis, biological evaluation, molecular docking and in silico physico-chemical properties. , 2017, Bioorganic & medicinal chemistry letters.

[71]  Christopher B. Cooper,et al.  7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis , 2017, Journal of medicinal chemistry.

[72]  Manoj Kumar Singh,et al.  Copper salisylaldoxime (CuSAL) imparts protective efficacy against visceral leishmaniasis by targeting Leishmania donovani topoisomerase IB. , 2017, Experimental parasitology.

[73]  G. Bressan,et al.  The expression of NTPDase1 and -2 of Leishmania infantum chagasi in bacterial and mammalian cells: Comparative expression, refolding and nucleotidase characterization. , 2017, Protein expression and purification.

[74]  S. Sundar,et al.  Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase , 2017, Journal of receptor and signal transduction research.

[75]  S. Sundar,et al.  Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation , 2017, Journal of biomolecular structure & dynamics.

[76]  M. Gramiccia,et al.  Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives , 2017, Journal of enzyme inhibition and medicinal chemistry.

[77]  Y. Pérez-Pertejo,et al.  Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of Leishmania infantum type IB DNA topoisomerase. , 2016, European journal of medicinal chemistry.

[78]  P. Yates,et al.  Arginase Is Essential for Survival of Leishmania donovani Promastigotes but Not Intracellular Amastigotes , 2016, Infection and Immunity.

[79]  Y. Pommier,et al.  Roles of eukaryotic topoisomerases in transcription, replication and genomic stability , 2016, Nature Reviews Molecular Cell Biology.

[80]  Partha Palit,et al.  Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis. , 2016, Biochimica et biophysica acta.

[81]  Glen Spraggon,et al.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[82]  A. Jardim,et al.  GMP reductase and genetic uncoupling of adenylate and guanylate metabolism in Leishmania donovani parasites. , 2016, Molecular and biochemical parasitology.

[83]  R. Agarwal,et al.  Identification of Leishmania donovani Topoisomerase 1 inhibitors via intuitive scaffold hopping and bioisosteric modification of known Top 1 inhibitors , 2016, Scientific Reports.

[84]  Simone Brogi,et al.  Verbascoside Inhibits Promastigote Growth and Arginase Activity of Leishmania amazonensis. , 2016, Journal of natural products.

[85]  V. Dubey,et al.  Novel Inhibitors of Ornithine Decarboxylase of Leishmania Parasite (LdODC): The Parasite Resists LdODC Inhibition by Overexpression of Spermidine Synthase , 2016, Chemical biology & drug design.

[86]  S. Chowdhury,et al.  A new bisbenzylisoquinoline alkaloid isolated from Thalictrum foliolosum, as a potent inhibitor of DNA topoisomerase IB of Leishmania donovani. , 2016, Fitoterapia.

[87]  F. Arvelo,et al.  In vitro activity of synthetic tetrahydroindeno[2,1-c]quinolines on Leishmania mexicana. , 2015, Parasitology international.

[88]  L. A. Calderon,et al.  The effect of 3β, 6β, 16β-trihydroxylup-20(29)-ene lupane compound isolated from Combretum leprosum Mart. on peripheral blood mononuclear cells , 2015, BMC Complementary and Alternative Medicine.

[89]  J. Finch,et al.  Spotlight on tavaborole for the treatment of onychomycosis , 2015, Drug design, development and therapy.

[90]  A. Echevarria,et al.  Antileishmanial activity and trypanothione reductase effects of terpenes from the Amazonian species Croton cajucara Benth (Euphorbiaceae). , 2015, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[91]  S. Sundar,et al.  Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach , 2015, Journal of biomolecular structure & dynamics.

[92]  F. Angelucci,et al.  Leishmania infantum trypanothione reductase is a promiscuous enzyme carrying an NADPH:O2 oxidoreductase activity shared by glutathione reductase. , 2015, Biochimica et biophysica acta.

[93]  L. Moreira-Dill,et al.  A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro , 2015, BMC Complementary and Alternative Medicine.

[94]  M. Siddiqi,et al.  Novel β-carboline–quinazolinone hybrid as an inhibitor of Leishmania donovani trypanothione reductase: Synthesis, molecular docking and bioevaluation , 2015 .

[95]  J. Pratap,et al.  Novel protein-protein interaction between spermidine synthase and S-adenosylmethionine decarboxylase from Leishmania donovani. , 2015, Biochemical and biophysical research communications.

[96]  M. S. Alexandre-Moreira,et al.  Synthesis, Leishmanicidal Activity and Theoretical Evaluations of a Series of Substituted bis-2-Hydroxy-1,4-Naphthoquinones , 2014, Molecules.

[97]  S. Chowdhury,et al.  Isobenzofuranone derivatives exhibit antileishmanial effect by inhibiting type II DNA topoisomerase and inducing host response , 2014, Pharmacology research & perspectives.

[98]  C. García-Estrada,et al.  Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery , 2014, International journal for parasitology. Drugs and drug resistance.

[99]  M. Sauvain,et al.  In Vitro and In Vivo Activity of Benzo[c]phenanthridines against Leishmania amazonensis , 2014, Planta Medica.

[100]  S. Wyllie,et al.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects , 2014, Trends in parasitology.

[101]  A. Monge,et al.  Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives , 2014, Parasitology Research.

[102]  J. Fernandes,et al.  Isolation of arginase inhibitors from the bioactivity-guided fractionation of Byrsonima coccolobifolia leaves and stems. , 2014, Journal of natural products.

[103]  S. Chowdhury,et al.  The lignan glycosides lyoniside and saracoside poison the unusual type IB topoisomerase of Leishmania donovani and kill the parasite both in vitro and in vivo. , 2013, Biochemical pharmacology.

[104]  O. Santos-Filho,et al.  Dietary flavonoids fisetin, luteolin and their derived compounds inhibit arginase, a central enzyme in Leishmania (Leishmania) amazonensis infection. , 2013, Food chemistry.

[105]  O. Santos-Filho,et al.  Inhibition of Leishmania (Leishmania) amazonensis and Rat Arginases by Green Tea EGCG, (+)-Catechin and (−)-Epicatechin: A Comparative Structural Analysis of Enzyme-Inhibitor Interactions , 2013, PloS one.

[106]  V. Dubey,et al.  Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[107]  S. Sundar,et al.  Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. , 2013, Experimental parasitology.

[108]  D. Christianson,et al.  Crystal structure of arginase from Leishmania mexicana and implications for the inhibition of polyamine biosynthesis in parasitic infections. , 2013, Archives of biochemistry and biophysics.

[109]  V. Yardley,et al.  Inhibition of Leishmania infantum Trypanothione Reductase by Azole‐Based Compounds: a Comparative Analysis with Its Physiological Substrate by X‐ray Crystallography , 2013, ChemMedChem.

[110]  V. Lutje,et al.  Chemotherapy for second-stage Human African trypanosomiasis. , 2010, The Cochrane database of systematic reviews.

[111]  C. Prieto,et al.  Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. , 2013, Biochemical pharmacology.

[112]  M. Vannier-Santos,et al.  Leishmanicidal activity of Cecropia pachystachya flavonoids: arginase inhibition and altered mitochondrial DNA arrangement. , 2013, Phytochemistry.

[113]  S. Sundar,et al.  Leishmaniasis: an update of current pharmacotherapy , 2013, Expert opinion on pharmacotherapy.

[114]  D. Sundar,et al.  A leishmaniasis study: structure-based screening and molecular dynamics mechanistic analysis for discovering potent inhibitors of spermidine synthase. , 2012, Biochimica et biophysica acta.

[115]  M. Jagannadham,et al.  Molecular docking based inhibition of Trypanothione reductase activity by Taxifolin novel target for antileishmanial activity , 2012 .

[116]  Michelle M. Cartagena,et al.  2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. , 2012, Bioorganic & medicinal chemistry letters.

[117]  Syamal Roy,et al.  The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice , 2012, EMBO molecular medicine.

[118]  Y. Pommier,et al.  Indotecan (LMP400) and AM13-55: Two Novel Indenoisoquinolines Show Potential for Treating Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.

[119]  A. Hailu,et al.  Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial , 2012, PLoS neglected tropical diseases.

[120]  J. Beijnen,et al.  Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.

[121]  C. M. Sant’Anna,et al.  Investigation of trypanothione reductase inhibitory activity by 1,3,4-thiadiazolium-2-aminide derivatives and molecular docking studies. , 2012, Bioorganic & medicinal chemistry.

[122]  Y. Pérez-Pertejo,et al.  Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. , 2012, Molecular and biochemical parasitology.

[123]  Daniel S. Palacios,et al.  Amphotericin primarily kills yeast by simply binding ergosterol , 2012, Proceedings of the National Academy of Sciences.

[124]  A. Roy,et al.  Development of Derivatives of 3, 3′-Diindolylmethane as Potent Leishmania donovani Bi-Subunit Topoisomerase IB Poisons , 2011, PloS one.

[125]  P. Yates,et al.  IMP dehydrogenase deficiency in Leishmania donovani causes a restrictive growth phenotype in promastigotes but is not essential for infection in mice. , 2011, Molecular and biochemical parasitology.

[126]  R. Madhubala,et al.  Leishmania donovani encodes a functional enzyme involved in vitamin C biosynthesis: arabino-1,4-lactone oxidase. , 2011, Molecular and biochemical parasitology.

[127]  S. Chowdhury,et al.  Novel Betulin Derivatives as Antileishmanial Agents with Mode of Action Targeting Type IB DNA Topoisomerase , 2011, Molecular Pharmacology.

[128]  A. Desideri,et al.  Conjugated Eicosapentaenoic Acid (cEPA) Inhibits L. donovani TopoisomeraseI and has an Antiproliferative Activity Against L. donovani Promastigotes , 2011 .

[129]  M. Gramiccia,et al.  A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition , 2011, Amino Acids.

[130]  M. Gramiccia,et al.  Inhibitory Effect of Silver Nanoparticles on Trypanothione Reductase Activity and Leishmania infantum Proliferation. , 2011, ACS medicinal chemistry letters.

[131]  V. Dubey,et al.  Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis , 2011, Molecular and Cellular Biochemistry.

[132]  Shyam Sundar,et al.  Antimony Toxicity , 2010, International journal of environmental research and public health.

[133]  F. Chappuis,et al.  High Mortality among Older Patients Treated with Pentavalent Antimonials for Visceral Leishmaniasis in East Africa and Rationale for Switch to Liposomal Amphotericin B , 2010, Antimicrobial Agents and Chemotherapy.

[134]  Peter G. Smith,et al.  Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial , 2010, PLoS neglected tropical diseases.

[135]  Sonja B. Braun-Sand,et al.  Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. , 2010, Future medicinal chemistry.

[136]  F. Frézard,et al.  Pentavalent Antimonials: New Perspectives for Old Drugs , 2009, Molecules.

[137]  R. Barker,et al.  Discovery of new S-adenosylmethionine decarboxylase inhibitors for the treatment of Human African Trypanosomiasis (HAT). , 2009, Bioorganic & medicinal chemistry letters.

[138]  B. Saha,et al.  Miltefosine Promotes IFN-γ-Dominated Anti-Leishmanial Immune Response1 , 2009, The Journal of Immunology.

[139]  R. Balaña-Fouce,et al.  Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. , 2009, Molecular and biochemical parasitology.

[140]  J. Nitiss.  DNA topoisomerase II and its growing repertoire of biological functions , 2009, Nature Reviews Cancer.

[141]  Nicole M. Baker,et al.  Structural studies of type I topoisomerases , 2008, Nucleic acids research.

[142]  G. Gerwig,et al.  9-O-acetylated sialic acids enhance entry of virulent Leishmania donovani promastigotes into macrophages , 2008, Parasitology.

[143]  M. Wilson,et al.  Leishmania donovani Ornithine Decarboxylase Is Indispensable for Parasite Survival in the Mammalian Host , 2008, Infection and Immunity.

[144]  T. Shapiro,et al.  Activity of Indenoisoquinolines against African Trypanosomes , 2008, Antimicrobial Agents and Chemotherapy.

[145]  Y. Pommier,et al.  Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance. , 2008, Biochemical pharmacology.

[146]  G. H. Coombs,et al.  Leishmania panamensis: comparative inhibition of nuclear DNA topoisomerase II enzymes from promastigotes and human macrophages reveals anti-parasite selectivity of fluoroquinolones, flavonoids and pentamidine. , 2007, Experimental parasitology.

[147]  O. Heby,et al.  Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasis , 2007, Amino Acids.

[148]  Y. Pérez-Pertejo,et al.  S-Adenosylmethionine in protozoan parasites: functions, synthesis and regulation. , 2007, Molecular and biochemical parasitology.

[149]  J. Engel,et al.  Development of miltefosine as an oral treatment for leishmaniasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[150]  A. Pegg.  Regulation of Ornithine Decarboxylase* , 2006, Journal of Biological Chemistry.

[151]  C. Cameron,et al.  Mechanisms of action of ribavirin against distinct viruses , 2005, Reviews in medical virology.

[152]  J. Berman.  Miltefosine to treat leishmaniasis , 2005, Expert opinion on pharmacotherapy.

[153]  R. Reguera,et al.  Polyamine transport in parasites: a potential target for new antiparasitic drug development. , 2005, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[154]  L. Persson,et al.  Proteasomal Degradation of a Trypanosomal Ornithine Decarboxylase , 2003, Cellular Physiology and Biochemistry.

[155]  L. Persson,et al.  Turnover of trypanosomal ornithine decarboxylases. , 2003, Biochemical Society transactions.

[156]  P. Myler,et al.  A Novel Active DNA Topoisomerase I in Leishmania donovani * , 2003, The Journal of Biological Chemistry.

[157]  D. Klinman,et al.  CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells , 2002, European journal of immunology.

[158]  D. Zilberstein,et al.  Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovani * , 2001, The Journal of Biological Chemistry.

[159]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[160]  I. D. Algranati,et al.  Sensitivity of trypanosomatid protozoa to DFMO and metabolic turnover of ornithine decarboxylase. , 2000, Biochemical and biophysical research communications.

[161]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[162]  I. D. Algranati,et al.  Trypanosoma cruzi epimastigotes lack ornithine decarboxylase but can express a foreign gene encoding this enzyme , 1999, FEBS letters.

[163]  R. Reguera,et al.  Interaction of cationic diamidines with Leishmania infantum DNA. , 1998, Biological chemistry.

[164]  R. Balaña-Fouce,et al.  Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. , 1996, Biochemical pharmacology.

[165]  Mark A. Murcko,et al.  Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.

[166]  R. Madhubala,et al.  Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. , 1996, Pharmacological research.

[167]  B. Tekwani,et al.  Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. , 1995, Molecular and biochemical parasitology.

[168]  R. Reguera,et al.  Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotes. , 1994, Life sciences.

[169]  R. Madhubala,et al.  Antileishmanial activity of berenil and methylglyoxal bis (guanylhydrazone) and its correlation with S-adenosylmethionine decarboxylase and polyamines. , 1995, The international journal of biochemistry & cell biology.

[170]  J. Champoux.  Mechanism of catalysis by eukaryotic DNA topoisomerase I. , 1994, Advances in pharmacology.

[171]  D. Warnock.  Amphotericin B: an introduction. , 1991, The Journal of antimicrobial chemotherapy.

[172]  F. Opperdoes,et al.  Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. , 1989, Molecular and biochemical parasitology.

[173]  D. Perrier,et al.  A stability study of amphotericin B in aqueous media using factorial design , 1988 .

[174]  B. Chait,et al.  Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. , 1985, Science.